# Regeneron Pharmaceuticals Inc (REGN) — Stock CV

Regeneron Pharmaceuticals Inc is a $76.8B healthcare company. Revenue grew 9.3% over the last year, it keeps 28¢ of every dollar of sales as profit, and it holds more cash than debt. It trades at 17.8× earnings — around the middle of its own history.

> Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation.

## Identity

- **Ticker**: REGN
- **Sector**: Healthcare
- **Industry**: Biotechnology
- **Headquarters**: TARRYTOWN, NY
- **Employees**: 15 410
- **Website**: https://www.regeneron.com
- **Market cap**: $76.8B
- **Last price**: $745.55
- **Financial profile**: Mixed

## Vitals (TTM)

- **Revenue**: $15.5B
- **Net income**: $4.33B
- **Free cash flow**: $3.76B
- **Net cash**: $6.62B
- **P/E**: 17.8
- **Revenue growth (YoY)**: 9.3%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 56 |
| Growth | 37 |
| Profitability | 77 |
| Health | 75 |
| Quality | 69 |
| Moat | 100 |

## Qualifications (beginner checklist) — 10 of 11 passed

- [x] Revenue growing — +9.3% YoY
- [x] Profitable — $4.33B TTM
- [x] Profit growing — +2.8% YoY
- [x] Generates cash — $3.76B TTM
- [x] Debt under control — more cash than debt
- [x] Established company — $76.8B market cap
- [x] Not printing shares — -5.6% shares over ~5y
- [x] Proven track record — 10/10 profitable years
- [ ] Financially stable — health score 50/100
- [x] Pays a dividend — yield 0.49%
- [x] Valuation not extreme — P/E 17.8

## Experience (career milestones)

- **2023** — Regeneron announced it would acquire Decibel Therapeutics
- **FY2021** — Revenue crossed $10B: $16.1B for the year
- **FY2021** — Best year on record: $8.08B net income
- **2018** — Libtayo was approved by the FDA in September 2018. * Inmazeb (atoltivimab/maftivimab/odesivimab) is a drug made of…
- **FY2016** — Profitable every year on record: 10 consecutive profitable years in our data
- **FY2016** — Revenue already above $1B: $4.86B in first reported year
- **FY2016** — Positive free cash flow every year since: 10-year streak
- **1988** — The company was founded in 1988

## Strengths

- High gross margin (86.0%)
- Strongly profitable — 27.9% net margin
- Strong cash conversion — FCF is 24.2% of revenue
- Net cash position after subtracting debt from cash
- Interest covered 50.0× by operating earnings

## Watch-outs

- None stand out in the data.

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $16.1B | $8.08B | $6.53B |
| FY2022 | $12.2B | $4.34B | $4.42B |
| FY2023 | $13.1B | $3.95B | $3.88B |
| FY2024 | $14.2B | $4.41B | $3.66B |
| FY2025 | $14.3B | $4.50B | $4.08B |

---

Source: https://stockcv.com/REGN — derived from company filings; may be delayed or incomplete. Information, not investment advice.